September 2, 2008
Sanofi-Aventis Wins Japanese Approval for Taxotere to Treat Prostrate Cancer
Sanofi-Aventis has announced that the Japanese Ministry of Health, Labor and Welfare has granted an approval for use of Taxotere injection in prostate cancer.
Taxotere is already approved in Japan for the treatment of breast cancer, non-small cell lung, gastric, head and neck, ovarian, esophageal and endometrial cancers.
This new approval is based on the results of an international large-scale Phase III clinical study TAX327 and on a Japanese Phase II clinical trial.